Owing to the heterogeneity of cancer, oncology markets are increasingly focusing on personalized therapy approaches that are expected to provide greater efficacy gains. Driving this trend are biomarkers that effectively identify the niche patient populations most likely to respond and derive benefit from targeted therapies. Biomarkers are already entrenched in oncology indications such as breast, colorectal, gastric, and non-small-cell lung cancers and malignant melanoma, where biomarker-driven prescribing has proven highly lucrative.

Questions Answered in This Report:

  • Biomarker testing is standard practice in most indications covered in this report. Which biomarkers are tested routinely and in which patient subpopulations? What factors, if any, impact further penetration of biomarker testing? Why do penetration rates differ among oncology indications?

  • Numerous novel therapies in late-stage development are evaluated in molecularly defined patient subpopulations. How will key current biomarker-driven therapies compete with emerging therapies? How will physicians choose between biomarker-driven therapies?

  • The pipelines of oncology indications discussed in this report contain several therapies evaluated in novel molecularly-defined patient populations. How will biomarker testing and prescribing change in the future? Which novel biomarkers are anticipated to enter the diagnosis pathway of these oncology indications? What will be the main hurdles, if any, physicians and pathologists face in incorporating novel biomarkers in routine practice?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 20 country-specific interviews with medical oncologists and pathologists.

Epidemiology: Incidence of breast, colorectal, gastric, ovarian, and non-small-cell lung cancers and malignant melanoma by country.

Population segments in market forecast: Breast cancer (adjuvant/neoadjuvant; first-line, advanced/metastatic; second- and subsequent-line, advanced metastatic); gastric cancer (first-line, metastatic; second- and third-line, metastatic); colorectal cancer (first-line, metastatic; second- and third-line, metastatic); ovarian cancer (first-line, advanced; second-line, platinum-sensitive, advanced; second-line, platinum-resistant, advanced; third- and fourth-line, advanced); non-small-cell lung cancer (first-line, advanced/metastatic; second- and third-line, advanced/metastatic); malignant melanoma (first-line, unresectable/metastatic; second- and third-line).

Emerging therapies: Phase II: 3 drugs; Phase III: 14 drugs; registered: 4 drugs.

Market forecast features: Using a proprietary patient-flow model incorporating mortality, we forecast drug sales for all patient segments annually through 2022.

Author(s): Amy Duval, M.Res.
Orestis Mavroudis-Chocholis, Ph.D.

Related Reports

Biosimilars - Market Events And Forecast - Oncology

In 2019, sales of branded monoclonal antibody biologics in oncology exceeded $18 billion across the major markets (United States, EU5, and Jap...

View Details

Biomarkers In Oncology - Access & Reimbursement - Detailed, Expanded Analysis (US) Biomarkers In Oncology

Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malig...

View Details

Biosimilars - Geographic Focus: China - Biosimilars | China In-Depth | Oncology And Immunology | China

The approval of Shanghai Henlius Biotech's HLX01—a biosimilar of Roche's Rituxan (rituximab)—in February 2019 marked the beginning of the biosimilars era in China. Since then, b...

View Details

Biosimilars - Emerging Biosimilars - Special Topics: Oncology Biosimilars In The United States - Wave 2

Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the seco...

View Details